Today's Date: June 4, 2023
Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Developme   •   Statement by the Prime Minister to mark four years since the publication of the final report of the National Inquiry into Missin   •   GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting   •   Tips for a smooth transition to senior living from the San Luis Obispo assisted living professionals   •   Cupshe Celebrates 8th Birthday with Exclusive Collection in Collaboration with Chanel Iman, Heather Rae El Moussa, and Brittany   •   Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipili   •   Dorsett Wanchai Marks World Environment Day 2023 with Bold Paperless and Plastic-Free Sustainability Initiatives   •   Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023   •   ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Pl   •   Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y   •   Bijou Ikli named new CEO by Florida Assisted Living Association   •   TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years   •   Air Canada's Inaugural Amsterdam-Montreal Route Takes Off; Uplifts Sustainable Aviation Fuel in Amsterdam   •   Government of Canada releases summary of actions taken to address the safety and wellbeing of Indigenous women, girls and 2SLGBT   •   New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing   •   Reigniting the Cancer Moonshot: Massive Bio Joins CancerX as Founding Member to Accelerate Innovation and AI Implementation in C   •   Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclit   •   Research Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different P   •   Statement by the Prime Minister on Canadian Armed Forces Day   •   High Schooler empowers Youth with Nonprofit "Unlimited Potential", raises $100,000 for Sports Medicine Research and Advocacy
Bookmark and Share

InvisiShield Technologies Collaborates with Gladstone Institutes to Accelerate Development of Intranasal Preventatives against S

EMERYVILLE, Calif. , March 20 /Businesswire/ - InvisiShield Technologies Ltd., a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses, today announced a collaboration with Gladstone Institutes to develop intranasal preventatives against airborne infection, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV).

Gladstone Institutes, a non-profit biomedical research organization that uses visionary science and technology to overcome disease, will leverage its expertise in immunology and virology to support the collaboration. Gladstone has made significant contributions to better understanding and developing new therapies for a range of viral diseases, including HIV/AIDS and COVID-19.

The collaboration aims to develop intranasal preventatives that can protect individuals from viral infections, including SARS-CoV-2, the virus that causes COVID-19, as well as influenza and RSV. Intranasal preventatives have the potential to serve as an immediate line of defense against viral infections, irrespective of an individual’s vaccination or immune system status, by targeting the nose and upper respiratory tract where most infections originate.

Under the terms of the collaboration, InvisiShield will provide funding and technical support for the development of intranasal preventatives, while Gladstone scientists will conduct preclinical studies to evaluate the safety and efficacy of the product, including in its state-of-the-art Biosafety Level 3 (BSL-3) facility where live virus tests can be conducted.

“We are excited to be collaborating with Gladstone to develop intranasal preventatives for three of the most important respiratory viral infections, SARS-CoV-2, influenza, and RSV,” said Dr. Warner Greene, President, Chief Scientific Officer, and Co-Founder of InvisiShield. “By combining our expertise in biotechnology with Gladstone’s strengths in immunology and virology, we hope to quicken the pace of discovery and development of preventatives for these global infectious threats.”

“By joining our expertise and resources in immunology and virology with InvisiShield’s innovative ‘capture and kill’ technology, we are well positioned to create a novel and powerful tool in the fight against viral infections,” said Dr. Melanie Ott, Director of the Gladstone Institute of Virology and Chair of InvisiShield’s Scientific Advisory Board.

InvisiShield Technologies and Gladstone are committed to advancing medical research and addressing unmet medical needs. This collaboration is expected to yield new approaches to disease prevention that are safe, effective, and easy to administer.


The InvisiShield COVID-19 intranasal preventive (IS101) is designed as a topical daily use nasal spray to provide immediate protection against SARS-CoV-2 infection, regardless of a person’s vaccination or immune system status. IS101 binds SARS-CoV-2 and has a proprietary nasal retention technology. It has the capacity to both “capture and kill” all major current and potential future SARS-CoV-2 variants in the nasal cavity, the primary entry point of infection. In pre-clinical studies, IS101 provided at least 10 hours of protection against infection in mice.


Founded by Dr. Warner Greene and Dr. Cheng Liu with technologies originally developed by Eureka Therapeutics, Inc., InvisiShield Technologies Ltd. (formerly known as InvisiMask Technologies Ltd.) is a pre-clinical-stage biotechnology company focused on developing intranasal preventives to prevent COVID-19 from all major current and potential future SARS-CoV-2 variants using our proprietary “capture and kill” technology. Our proprietary technology platform is being applied to other respiratory viruses, including influenza and RSV.

InvisiShield Technologies Ltd. is headquartered in the San Francisco Bay Area. For more information on InvisiShield, please visit

STORY TAGS: California, Health, Medical Devices, Infectious Diseases, COVID-19, General Health, Pharmaceutical, Biotechnology, Product/Service, United States, North America,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News